Genocea Biosciences Net Income

Genocea Biosciences (GNCA) currently reports a net income of $-39M as of March 2022. That compares with $-43M in the prior-year period — up 8.4% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Genocea Biosciences's net income history and peer comparisons.

Genocea Biosciences's net income increased from $-43M to $-39M — a 8.4% year-over-year increase (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Genocea Biosciences's net income of $-39M is lower than the Healthcare sector average of $16B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Genocea Biosciences reported $-39M in net income as of March 2022. That compares with $-43M in the prior-year period — up 8.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-39M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Genocea Biosciences, and consider following GNCA for alerts when major investors trade the stock.